Bayer

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

EFORT Publication Schedule

Ladies and Gentlemen,

Rivaroxaban data from the RECORD4 clinical trial will be presented at the annual meeting of the European Federation of National Associations of Orthopaedics & Traumatology (EFORT) taking place in Nice, France. On this occasion we are planning the following publications:

May 26, 2008 12:00 noon CEST	**Internet address for all information material and webcast:** www.investor.bayer.com / www.investor.bayer.de ■ Webcast details ■ Additional background material ■ List of EFORT abstracts on Rivaroxaban
May 30, 2008 01:00 p.m. CEST	**Press release on Rivaroxaban data presented at the EFORT congress**
05:30 p.m. CEST	**Investor Conference Call to review Rivaroxaban data presented at the EFORT congress** with Alexander G.G. Turpie, M.D., Chair of the steering committee and lead investigator RECORD4 study Dr. Kemal Malik, Head of Global Development at Bayer Schering Pharma, Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development, and Dr. Alexander Rosar, Head of Investor Relations
	Dial-in Numbers **International: +44 207 153 2027** **UK: 0207 153 2027** **US: +1 800 762 9439** **Germany: 06103 485 3000** If you are unable to participate in the conference, a recording will be available for access by touch tone telephone until June 4, 2008. Live audio broadcast (English only) available on the Internet.
approx. 9:00 p.m. CEST	**Replay Dial-in Numbers** **International: +44 207 190 5901, Passcode: 139425#** **UK: 0207 190 5901, Passcode: 139425#** **US: +1 303 590 3030, Passcode: 3878190#** **Germany: 069 58999 0568, Passcode: 139425#** On-demand version of the conference call webcast available on the Internet.

CEST = Central European Summer Time = GMT + 2 hours

Best regards,

Bayer Investor Relations